Simultaneous Inhibition of MEK and CDK4 Leads to Potent Apoptosis in Human Melanoma Cells
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Deregulation of RAS-RAF-MEK-ERK and p16INK4A-cycylin D:CDK4/6-RB pathways is important for melanoma development. Chemotherapeutic agents targeting both pathways were developed but results of clinical studies with monotherapies were disappointing. We examined the effect of cotargeting both pathways with MEK inhibitor PD98059 and CDK4 inhibitor 219476 on human melanoma cells lines, and found that combinatorial treatment dramatically increased apoptosis compared to the single agent treatment. The apoptosis was associated with downregulation of BCL2, BCL2L1, BIRC5, and upregulation of BIM. Our results indicate that simultaneously targeting ERK and RB pathways is a promising strategy for melanoma treatment and should encourage further in-depth investigations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“combined CDK4 and MEK inhibition has led to increased apoptosis and/or reduced viability in colony formation assays in human melanoma and pancreatic cancer cell lines.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [106]
In the citing paper
“preclinical synergistic effects of CDK4/6 inhibition and MAP kinase inhibition in melanoma and pancreatic cancer models has stimulated substantial interest in the development of these combinations (106-108)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [106]
Citations
Cites
1 retracted
The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells
Panka, D. J., Wang, W., Atkins, M. B., & Mier, J. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-0808 · Cited by 167
RetractedMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674 · cited 2×
“Cells were treated with solvent vehicle control (1), PD98059 (2),”
MethodDistinct Sets of Genetic Alterations in Melanoma
Curtin, J. A., Fridlyand, J., Kageshita, T., Patel, H. N., Busam, K. J., Kutzner, H., Cho, K.-H., Aiba, S., Bröcker, E.-B., LeBoit, P. E., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050092 · Cited by 2,747
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,176
Petitjean, A., Mathe, E., Kato, S., Ishioka, C., Tavtigian, S. V., Hainaut, P., & Olivier, M. (2007) · Human Mutation · doi:10.1002/humu.20495 · Cited by 1,598 · cited 1×
“Sequencing analysis of TP53 cDNA (17) showed that 624Mel and OM431cells respectively harbor a T1076G (Cys275Trp) and a G1048A (Gly266Glu) mutations in the DNA binding domain that is likely to compromise the transcription and apoptosis function of p53 (29).”
BackgroundA p16 INK4a -Insensitive CDK4 Mutant Targeted by Cytolytic T Lymphocytes in a Human Melanoma
Wölfel, T., Hauer, M., Schneider, J., Serrano, M., Wölfel, C., Klehmann-Hieb, E., De Plaen, E., Hankeln, T., Meyer zum Büschenfelde, K.-H., & Beach, D. (1995) · Science · doi:10.1126/science.7652577 · Cited by 1,154
A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
The Regulation of INK4/ARF in Cancer and Aging
Kim, W. Y., & Sharpless, N. E. (2006) · Cell · doi:10.1016/j.cell.2006.10.003 · Cited by 1,009 · cited 1×
“Deregulation of the p16INK4A-cyclin D:cyclin-dependent kinases (CDK) 4/6-retinoblastoma (RB) pathway is a common paradigm in malignancy including melanoma (7, 8) and represents another attractive target in melanoma treatment.”
BackgroundGermline mutations in the p16INK4a binding domain of CDK4 in familial melanoma
Zuo, L., Weger, J., Yang, Q., Goldstein, A. M., Tucker, M. A., Walker, G. J., Hayward, N., & Dracopoli, N. C. (1996) · Nature Genetics · doi:10.1038/ng0196-97 · Cited by 818 · cited 1×
“A germ-line Arg24Cys (R24C) mutation in CDK4 was identified in familial melanoma patients (12, 13).”
BackgroundTumor suppression by Ink4a-Arf: progress and puzzles.
Lowe, S. W., & Sherr, C. J. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00013-8 · Cited by 699 · cited 1×
“Both ERK signaling and CDK4/6 kinase have been shown to regulate RB protein and cell cycle progression (14, 15).”
Background
Research works printed but not linked: 2
- Dong J., 2003, Cancer Res, 63, 3883
- Chang F., 2003, Int J Oncol, 22, 469
Cited by
Targeting CDK4 and CDK6: From Discovery to Therapy
Sherr, C. J., Beach, D., & Shapiro, G. I. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0894 · Cited by 936
Targeting the MAPK pathway in melanoma: Why some approaches succeed and other fail
Inamdar, G. S., Madhunapantula, S. V., & Robertson, G. P. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.029 · Cited by 225
Senescence as a therapeutically relevant response to CDK4/6 inhibitors
Wagner, V., & Gil, J. (2020) · Oncogene · doi:10.1038/s41388-020-1354-9 · Cited by 148
Bisi, J., Sorrentino, J. A., Jordan, J. L., Darr, D. D., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2017) · Oncotarget · doi:10.18632/oncotarget.16216 · Cited by 65
Huang, G., Krocker, J. D., Kirk, J. L., Merwat, S. N., Ju, H., Soloway, R. D., Wieck, L. R., Li, A., Okorodudu, A. O., Petersen, J. R., et al. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0885 · Cited by 62
Self-citation
Metadata
- Authors
- Li, J., Xu, M., Yang, Z., Li, A., & Dong, J.
- Affiliations
- The University of Texas Medical Branch at Galveston (US)
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2010-04
- Volume
- 28
- Issue
- 4
- Pages
- 350-356
- ISSN
- 0735-7907 (ISSN-L)
- 1532-4192
- OpenAlex
- W4246458160
- Cited by
- 26
- References
- 31
- Citations by year
- 2022: 1 · 2020: 1 · 2018: 4 · 2017: 1 · 2015: 2 · 2014: 5 · 2013: 3 · 2012: 3
- FWCI
- 1.56
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Investigation (publishedVersion)
- Funders
- Cancer and Leukemia Group B Foundation
- Melanoma Research Alliance
- Harry J. Lloyd Charitable Trust
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- melanoma, MEK inhibition, CDK4 inhibition, PD98059, combination therapy, apoptosis, RAS/MAPK pathway, Bcl-2, Bcl-xL, survivin, building information modeling, tumor suppressor proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Simultaneous Inhibition of MEK and CDK4 Leads to Potent Apoptosis in Human Melanoma Cells. https://app.cochat.ai/papers/10.1080/07357900903286966
- The paper
- Li, J., Xu, M., Yang, Z., Li, A., & Dong, J. (2010). Simultaneous Inhibition of MEK and CDK4 Leads to Potent Apoptosis in Human Melanoma Cells. Cancer Investigation. https://doi.org/10.1080/07357900903286966
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.